Resistance Pathways and Innovative Therapies in Glioblastoma

Dear Colleagues,

Despite the major and constant efforts of the past 20 years, patients suffering from glioblastoma (GBM), the most frequent and deadly primary brain tumor, still have a very poor prognosis. Despite standard treatments combining surgical resection, when possible, radiochemotherapy and, recently, tumor-treating fields, these GBMs almost invariably recur. This rapid relapse is notably due to the diffuse infiltrative growth of GBM cells in the surrounding brain tissue, the pronounced intratumoral heterogeneity, the presence of GBM stem cells, a high tumor cell plasticity, a strong propensity to immune escape, and a high intrinsic resistance of GBM to cell death. In light of numerous recent fundamental and preclinical studies, significant progress has been made in understanding the complex molecular processes underlying gliomagenesis and treatment resistance in GBM, identifying a number of potential new targets and therapeutic strategies for the treatment of these highly aggressive brain tumors. The new engaging therapeutic options aim, in combination with conventional therapy, to exploit the specific flaws of GBM via high-precision treatments and possibly through personalized approaches. We welcome original research papers and review articles focusing on recent advances in this challenging area of research.

This Special Issue is supervised by Prof. Dr. Anthony Lemarié and assisted by our Topical Advisory Panel Member Dr. Augustin Le Naour (Tumor Radioresistance, from Signalling Pathways to Therapy, Department of Experimental Therapeutics, Inserm U1037 Toulouse Cancer Research Center (CRCT) & IUCT, 2 av. Hubert Curien, 31100 Toulouse, France).

Dr. Anthony Lemarié
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• glioblastoma
• cancer stem cells
• radioresistance
• chemoresistance
• targeted therapies
• tumor plasticity
• tumor heterogeneity
• invasion
• immune escape